|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (3Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
Juniper Pharmaceuticals (JNP) delivered earnings and revenue surprises of -450.00% and -6.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Boston-based company said it had a loss of 14 cents per share. The pharmaceutical company posted revenue of $15.3 million in the period. Juniper Pharmaceuticals shares have more than doubled since ...
Signs Agreement to be Acquired by Catalent, Inc. CRINONE® Revenues Increased 12% and Juniper Pharma Services (JPS) Revenues Increased 41% for the Six-months Ended June 30, 2018 vs. Prior Year BOSTON , ...